Compare Novavax Inc (NVAX) vs YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF (QDTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF — how do they compare? Novavax Inc trades at $12.75 (market cap $1.82B), while YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF trades at $39.27 (market cap $28.69M). The key difference: Novavax Inc is far larger — about 63.4× YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF's market cap, and Novavax Inc is trading nearer its 52-week high, YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Novavax Inc for 59 Days and YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF for 61 Days on average.
| NVAX | QDTY | |
|---|---|---|
Market Cap | $1.82B | $28.69M |
Volume | 6,198,505 | 22,490 |
Sector | Health | Income / Options Overlay |
52-Week High | $12.75 | $46.71 |
52-Week Low | $6.22 | $36.57 |
Typical Hold Time | 59 Days | 61 Days |
Enterprise Value | $1.39B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $11.01, down 1.87% on the day, with a bullish technical signal from moving averages and strong analyst support (73.9% buy ratings). The company reported revenue of $1.12B in 2025 with a net income of $440.3M, marking a significant turnaround from prior losses, though 2026 projections show a return to negative net income. Recent news highlights regulatory approvals for its COVID-19 vaccine and strategic pivots toward its Matrix-M adjuvant platform through partnerships.
The outlook is mixed: strong valuation ratios (P/E of 3.14, EV/EBITDA of 1.72) and recent earnings beats suggest undervaluation, but persistent cash burn and negative equity pose risks. Investment opportunity lies in partnership-driven growth, while risks include execution challenges and reliance on vaccine demand. Wall Street sentiment remains optimistic despite fundamental volatility.
QDTY trades at $39.27, down 0.84% today, with a bullish technical signal supported by moving averages. The ETF demonstrates strong dividend distribution activity with recent payouts ranging from $0.19 to $0.30 per share, highlighted by a $0.24 dividend announced October 6th, 2026 representing a significant yield. Technical indicators show mixed signals with RSI suggesting potential overbought conditions while overall trend remains positive.
The outlook remains favorable for income-focused investors given the consistent dividend payments, though elevated RSI levels suggest near-term caution. Key risks include market volatility affecting covered call strategies and interest rate sensitivity. The ETF's weekly distribution model provides regular income but requires monitoring of underlying Nasdaq 100 performance for sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF
QDTY is an actively managed ETF that employs a synthetic covered call strategy on the Nasdaq-100 Index using zero-days-to-expiration (0DTE) options. It aims to generate high weekly income by selling daily call options, providing limited participation in the index's upside while remaining fully exposed to its downside risk.
Read more on QDTY →
